SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sam Citron who wrote (670)12/17/2001 12:39:51 PM
From: Harold Engstrom  Read Replies (1) of 717
 
Rick's pointer to Peter's earlier post was actually informative, while my post was not really (I apologize.)

But, I really think that you intuited the answer that many might like to expound on but don't want to just flame management.

I owned PCYC on three separate occaissions - buying when it tanked and selling when it spiked (luckily). The Feuerstein column Peter references sobered me enough to stop considering it after the last purchase. While I owned it, I found out nothing from the company when I called (although they were polite.)

I would not buy PCYC at this point. It is analogous to PRCS, which I do own and think is a better play (if you want to live dangerously with a biotech trading at cash.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News